



## FLORIDA SOCIETY OF CLINICAL ONCOLOGY FAX BLAST – May 7, 2008

### **MEMBER NEWS:**

#### **Space Coast Medical Associates opens new Cancer Center:**

Dr. Richard Levine, immediate Past President of FLASCO, has opened a new cancer center in Titusville. The Titusville Space Coast Cancer Center is a comprehensive facility which offers a chemotherapy infusion center, state-of-the-art radiation therapy, diagnostic imaging with PET/CT and CT, full laboratory services, clinical trials, conference room for support groups and educational seminars, resource center, and patient advocate and navigator. **Congratulations** to Dr. Levine and the other physicians in this practice!

#### **MESSAGE FROM FLASCO PRESIDENT: Robert Cassell, MD**

One of the goals of our recent ASCO State Affiliate Grant is to identify and compile a list of all oncology PAs and NPs in the State of Florida. **Please send the FLASCO Executive Director the names, mailing address, telephone number, fax number and e-mail address for your PAs and NPs. (Dorothy.Green@cancer.org)**

#### **LEGISLATIVE UPDATE: Erin Dunbar, MD, Chairman**

CS/CS/CS/S1048 (Pedigree Bill) passed last Thursday. A more detailed explanation about the Bill's final wording and impact will be forthcoming. Thanks to all of you who helped with this Bill. In the near future there will be more updates on additional issues for FLASCO to support.

#### **FLASCO CLINICAL TRIALS NETWORK: Randal Henderson, MD, Chairman**

##### **Flasco Clinical Trials New Website:**

We are happy to announce that the FLASCO Cancer Trials Network website is now available at [www.fctn.org](http://www.fctn.org). The website was built using funds from an ASCO grant. .

The website has 2 main divisions, PATIENTS and MEDICAL PROFESSIONALS. The patient side includes information on clinical trials, the names and locations of network members, as well as extensive educational and supportive information for cancer patients, their families and caregivers. The professional side includes the names and contact information of the FCTN staff with a link to the FLASCO website, a list of network members, a list of clinical trials available, a sponsor section that lists our services, sections for professional news and conference coverage and a meeting calendar. Informational brochures for patients, potential sites and potential sponsors are also posted on the website.

Future plans for the website include a Members section to be accessed by password only. This section will be used to post copies of protocols, consents, data forms, and general communication with our members.

If you are a member of FCTN and would like to add this link to your practice website so that you and your patients can easily access this valuable resource, please e-mail your website address to Janice Grimes at [janicewgrimes@bellsouth.net](mailto:janicewgrimes@bellsouth.net)

#### **Searching for Trials:**

The FLASCO Cancer Trials Network (FCTN) is actively searching for clinical trials that would be of interest to our members. Cephalon has informed us that they are interested in investigator initiated concepts using their drug Treanda, which was recently approved by the FDA for use in CLL, in novel combinations in the following diseases: CLL, NHL, multiple myeloma and small cell lung cancer. If you would like to submit a concept for a study to be done by FCTN, please contact Randal Henderson, MD, at 904.716.1085 or Janice Grimes at 912.258.2333.

#### **CMS UPDATES:**

##### **Follow Up from the Recent End-Stage Renal Disease Open Door Forum**

CMS is offering members of the End-Stage Renal Disease (ESRD) provider community and other ESRD stakeholders a venue to submit questions about the newly published ESRD Conditions for Coverage (CfCs). Their goal is to provide responses that will help inquirers understand the new requirements. They are requesting that members of the ESRD renal community submit questions pertaining to the ESRD CfCs to the CMS ESRD\_Final\_Rule\_Rollout mailbox at [ESRD\\_Final\\_Rule\\_Rollout@cms.hhs.gov](mailto:ESRD_Final_Rule_Rollout@cms.hhs.gov) beginning May 12, 2008. Please submit only questions that pertain to the CfCs, as they will only answer these questions, and on a rolling basis. They will also try to communicate the questions and answers in the most efficient manner back to stakeholders. The CMS goal is to be as timely as possible with responses, but they cannot commit to a prescribed schedule.

Questions pertaining to ESRD payment, claims processing, Network activity, and survey and certification issues should be directed to your usual contact within CMS. Please contact Lynn Riley at 410-786-1286 or Lauren Oviatt at 410-786-4683 with questions about this announcement.

**New:**

**SE0814 – Provider Authentication by Medicare Provider Contact Centers**  
<http://www.cms.hhs.gov/MLNMArticles/downloads/SE0814.pdf>

**MM5972 – Prolonged Services (Codes 99354 - 99359)**  
<http://www.cms.hhs.gov/MLNMArticles/downloads/MM5972.pdf>

**MM6000 – Ambulance Fee Schedule - Conversion Factor File for CY 2009 Ambulance Inflation Factor**  
<http://www.cms.hhs.gov/MLNMArticles/downloads/MM6000.pdf>

**MM5860 – Adjusting Inpatient Prospective Payment System (IPPS) Reimbursement for Replaced Devices Offered Without Cost or With a Credit**  
<http://www.cms.hhs.gov/MLNMArticles/downloads/MM5860.pdf>

**MM5867 – Billing Blood and Blood Products**  
<http://www.cms.hhs.gov/MLNMArticles/downloads/MM5867.pdf>

**MM6043 – Blood-Derived Products for Chronic, Non-Healing Wounds**  
<http://www.cms.hhs.gov/MLNMArticles/downloads/MM6043.pdf>

**Revised:**

**MM5567 – Reporting of Additional Data to Describe Services on Hospice Claims**  
<http://www.cms.hhs.gov/MLNMArticles/downloads/MM5567.pdf>

**COA REQUEST:**

COA is requesting assistance from FLASCO to help in the compilation of a state of Florida template. COA has compiled an impact template for the state of Mississippi, with Iowa and Nebraska soon to follow. Included are cancer statistics for that state in relation to the entire United States. Topics such as poverty levels, uninsured population, cancer diagnoses and deaths annually are included.

There are also personal statements from practices about the impact of MMA via reduced reimbursement for drugs and services, access and quality issues. Patient testimonials are incorporated into this document, making a bold statement about how all facets of cancer care have been affected, often times with a different twist depending upon where you are located geographically.

If you would be willing to make such attestations, please contact: **Mary Kruczynski**, Director of Policy Analysis, Community Oncology Alliance - **215-630-5019**

**EDUCATIONAL OPPORTUNITIES:**

**Webinar on "Comparative Effectiveness."** - AstraZeneca invites you to participate in an informative As you may already be aware, congress's move toward creating a national center on comparative effectiveness raises a big question for industry:

"How will the data generated by this research be used by insurance companies?". This Webinar is offered through the Xcenda division of AmeriSourceBergen Specialty Group free of charge on Tuesday, May 20, 2008 from 1:00 to 2:00pm Central Daylight Time. To register, please go to <http://absgwebcasts.com>

**Live Webcast “Understanding Adherence to Oral mediation: Early Breast Cancer”** – Astra Zeneca invites you to participate in this web conference on Monday, May 12, 2008 – 12:00 Noon. Speaker: Jennie Crews, MD, Director of Medical Oncology, Marion L. Shepard Cancer Center-Beaufort County Hospital. Dial in number: 800.860.2442, Participant code: (Crews) – conference details may be found at: [www.inquisit.org/igast/astrazeneca.aspx](http://www.inquisit.org/igast/astrazeneca.aspx).

**Webcasts “Case Discussions in metastatic Breast Cancer.”** Lilly Oncology invites you to participate in this webcast. Speaker: Denise Yardley, MD, Program Director, Breast Cancer Research, The Sarah Cannon Research Institute. Webcasts are offered as follows: May 1, 12:15 PM; May 22, 1:15 PM, and May 29, 3:15 PM (all EST). To register: <http://www.medconference.net/breast>

**DISCLAIMER:** FLASCO has not reviewed these programs and “any views presented are not the views of FLASCO”

### **CORPORATE MEMBERSHIP/SPONSORSHIP: (January 1 – December 31, 2008)**

FLASCO Members extends a big thanks to all of our 2008 Corporate Members/Sponsors

#### **PLATINUM**

Astra Zeneca  
Bayer/Onyx  
Cephalon Oncology  
Eli Lilly  
Oncology Supply/ION  
Sanofi-Aventis  
OPR  
Pharmion  
AMGEN  
Genentech  
Abraxis Oncology.  
Ortho Biotech

#### **GOLD**

Celgene  
Genomic Health  
Novartis  
Pfizer  
Roche  
GlaxoSmithKline  
Bristol Myers Squibb  
Wyeth

#### **SILVER**

MGI Pharma  
US Oncology  
ImClone Systems  
OSI Pharmaceuticals  
Millennium Pharmaceuticals, Inc.

#### **BRONZE**

Boehringer Ingelheim  
Pharmaceuticals, Inc.  
Alexion

#### **FLASCO EVENTS:**

**August 8-9, 2008** – FLASCO Executive Committee Retreat – Marriott World Center Hotel - Orlando

**November 7-8, 2008** – FLASCO Fall Meeting – Tampa Airport Marriott Hotel

**February 27 & 28, 2009** – FLASCO Spring Meeting – Marriott Sawgrass - Jacksonville

**FLASCO Contact Information:** Dorothy Green Phillips, Executive Director -3709W. Jetton Ave., Tampa, Florida 33629 - Tel: 800.444.1410, Ext. 4410 - Cell Phone: 813.294.2620 - Fax: 813.254.5857 or 813.349.4472  
Email: [Dorothy.Green@cancer.org](mailto:Dorothy.Green@cancer.org)

#### **OTHER EVENTS:**

May 30 – June 4, 2008 – ASCO Annual Meeting - Chicago

September 17-20, 2008 – ACCC 25<sup>th</sup> National Oncology Economic Conference – San Francisco, California

September 19-20, 2008 - Annual ASCO/ASH/SGO Meeting of the Hematology/Oncology CAC Network

September 25-28, 2008 - Oncology Congress - the Hilton San Francisco

December 6-9, 2008 – ASH Annual meeting – San Francisco

February 5-8, 2009 - Florida Joint Cancer Conference – Orlando

February 26-28, 2009 – ASCO - GU Symposium, Orlando World Center Marriott

March 22-24, 2009 - 2009 AOHA Assembly Conference – Los Angeles, California